Dr Naomi Dempsey explains how she decides on an appropriate CDK4/6 inhibitor for patients receiving first-line treatment for metastatic HR+/HER- breast cancer.
Watch Dr. Naomi Dempsey, from Miami Cancer Institute, discuss the management of HER2-positive, early-stage disease during the CURE Educated Patient® Breast Cancer Summit at MBCC.
Patients with HER2-positive breast cancer often need to undergo aggressive treatment, but ongoing research is determining if chemotherapy can be scaled back for certain patients.